This is what analysts have to say about Novo Nordisk A/S (NYSE:NVO) after last week.

Novo Nordisk A/S (NYSE:NVO) Logo

Novo Nordisk A/S (NYSE:NVO) Ratings Coverage

Among 6 analysts covering Novo Nordisk (NYSE:NVO), 2 have Buy rating, 1 Sell and 3 Hold. Therefore 33% are positive. Novo Nordisk had 6 analyst reports since October 8, 2018 according to SRatingsIntel. The rating was downgraded by Bank of America on Monday, October 8 to “Neutral”. Jefferies reinitiated it with “Hold” rating and $285 target in Tuesday, December 11 report. The rating was upgraded by JP Morgan to “Overweight” on Monday, November 19. Below is a list of Novo Nordisk A/S (NYSE:NVO) latest ratings and price target changes.

14/12/2018 Broker: Morgan Stanley Rating: Equal-Weight Initiates Coverage On
11/12/2018 Broker: Jefferies Rating: Hold New Target: $285 Reinitiate
26/11/2018 Broker: HSBC Rating: Sell
26/11/2018 Broker: UBS Rating: Buy
19/11/2018 Broker: JP Morgan Old Rating: Neutral New Rating: Overweight Upgrade
08/10/2018 Broker: Bank of America Old Rating: Buy New Rating: Neutral Downgrade

The stock decreased 3.35% or $1.62 during the last trading session, reaching $46.92. About 978,102 shares traded. Novo Nordisk A/S (NYSE:NVO) has declined 10.81% since January 14, 2018 and is downtrending. It has underperformed by 10.81% the S&P500.

Novo Nordisk A/S, a healthcare company, engages in the discovery, development, manufacture, and marketing of pharmaceutical products worldwide. The company has market cap of $111.42 billion. It operates in two divisions, Diabetes and Obesity Care, and Biopharmaceuticals. It has a 19.06 P/E ratio. The Diabetes and Obesity Care segment provides insulins, GLP-1 analog, and oral anti-diabetic drugs, as well as other protein related products comprising glucagon, protein related delivery systems, and needles.

More notable recent Novo Nordisk A/S (NYSE:NVO) news were published by: Seekingalpha.com which released: “Lilly’s dual GIP and GLP-1 receptor agonist shows positive action in mid-stage T2D study; shares up 3% premarket – Seeking Alpha” on October 04, 2018, also Seekingalpha.com with their article: “Novo’s once-weekly somapacitan on par with daily Norditropin in mid-stage study – Seeking Alpha” published on September 28, 2018, Seekingalpha.com published: “Novo Nordisk: Time To Sell? – Seeking Alpha” on October 09, 2018. More interesting news about Novo Nordisk A/S (NYSE:NVO) were released by: Seekingalpha.com and their article: “Novo Nordisk’s Oral Diabetes Drug Is A Force To Be Reckoned With – Seeking Alpha” published on August 21, 2018 as well as Seekingalpha.com‘s news article titled: “Novo Nordisk’s oral semaglutide successful in late-state T2D study – Seeking Alpha” with publication date: October 26, 2018.

Novo Nordisk A/S (NYSE:NVO) Ratings Chart

(adsbygoogle = window.adsbygoogle || []).push({});

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.